Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP7 | P09237 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5485267 | 1.00 | BUB1 (0.34) | BUB1NR1H2GPR119MMP1MMP3 | |
| SCHEMBL5743293 | 0.83 | BUB1 (0.32) | BUB1 | |
| SCHEMBL25301908 | 0.79 | BUB1 (0.38) | BUB1NR1H2GPR119 | |
| SCHEMBL31456782 | 0.79 | BUB1 (0.38) | BUB1NR1H2GPR119 | |
| SCHEMBL350967 | 0.79 | BUB1 (0.38) | BUB1NR1H2GPR119 | |
| SCHEMBL28854066 | 0.77 | BUB1 (0.35) | BUB1NR1H2GPR119 | |
| SCHEMBL25331824 | 0.77 | BUB1 (0.35) | BUB1NR1H2GPR119 | |
| SCHEMBL2160689 | 0.75 | BUB1 (0.33) | BUB1NR1H2GPR119 | |
| SCHEMBL19510279 | 0.75 | BUB1 (0.33) | BUB1NR1H2GPR119 | |
| SCHEMBL5567921 | 0.74 | OXTR (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189754-B2 | Pyrrolidine ester derivatives with oxytocin modulating activity | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2007-03-13 | — | — | US | disclosed |
| US-20040147511-A1 | Pyrrolidine ester derivatives with oxytocin modulating activity | MERCK SERONO SA (CH) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147511-A1 | Pyrrolidine ester derivatives with oxytocin modulating activity | OXTR, OPRL1, OPRD1 | BUB1 4312/4885NR1H2 148/4885GPR119 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.